Table 1:

Treatments that sensitize LKB1 mutant tumors to ICB

Treatment	Effect	Reference #
All-trans retinoic acid	Reduced accumulation of MDSCs	92
Delivery of CCL21-expresssing dendritic cells	Enhanced recruitment of effector T cells	93
Palbociclib (CDK4/6 inhibitor)	Enhanced infiltration of ICAM1-driven T cells	94
Nanovesicle delivery of TUSC2	Increased infiltration of cytotoxic T cells, depletion of MDSCs	95
Anti-CTLA4	Increase iNOS+ antigen presenting cells and CD4+ effector cells	83
STAT3 antisense oligonucleotide	Reverse immunosuppressive inhibition of CD8+ cells by myeloid derived cells	96
MRT68921 (ULK1 inhibitor)	Increased infiltration of CD4+ and CD8+ T cells and enhanced immunoproteasome activity	98
Decitabine and BAY-1217389 (MPS1 inhibitor)	Activation of STING and enhanced T cell mediated antitumor immunity	100
Birinapant (IAP inhibitor)	Activation of STING and increased infiltration of CD8+ T cells	101